Costanzi J J, Loukas D, Gagliano R G, Griffiths C, Barranco S
Cancer. 1976 Oct;38(4):1503-6. doi: 10.1002/1097-0142(197610)38:4<1503::aid-cncr2820380410>3.0.co;2-9.
According to cell cycle synchrony principles, bleomycin was infused for 48 hours, followed by a dose of either methotrexate or hydroxyurea after a 24-hour rest, in 36 adult patients with disseminated carcinoma. In this preliminary study, a 59% response rate was noted among patients with epidermoid carcinoma of the head and neck. Four of four patients with transitional cell carcinoma of bladder and one patient with hypernephroma also responded. No responses were noted among five patients with epidermoid carcinoma of the lung. The length of response ranged from 1 to 8 months (median, 2 months). Seventy-seven percent of the responders had extensive prior radiotherapy. The first patient treated had fatal sepsis with leukopenia, which prompted a widening of the treatment interval. Subsequently, toxicity was mainly mild or absent, the moderate or severe toxicity was primarily neutropenia, which was reversible. The use of low-dose bleomycin infusion is safe and may play a role in cancer therapy in combination with other agents specific for certain tumors. The length of infusion should be determined by the cell cycle of the tumor, if its potential synchronizing capabilities are to be exploited.
根据细胞周期同步化原则，对36例成年播散性癌患者静脉输注博来霉素48小时，休息24小时后给予甲氨蝶呤或羟基脲一剂。在这项初步研究中，头颈部表皮样癌患者的缓解率为59%。4例膀胱移行细胞癌患者和1例肾上腺样瘤患者也有缓解。5例肺表皮样癌患者无缓解。缓解期为1至8个月（中位值为2个月）。77%的缓解者既往接受过广泛的放疗。首例接受治疗的患者因白细胞减少发生致命性脓毒症，这促使延长治疗间隔。随后，毒性主要为轻度或无毒性，中度或重度毒性主要为中性粒细胞减少，且可逆转。低剂量博来霉素静脉输注是安全的，与其他针对某些肿瘤的特异性药物联合应用时可能在癌症治疗中发挥作用。如果要利用其潜在的同步化能力，输注时间应根据肿瘤的细胞周期来确定。
